Publication:
Beta-3 adrenergic receptor overexpression reverses aortic stenosis-induced heart failure and restores balanced mitochondrial dynamics.

dc.contributor.authorPun-García, Andrés
dc.contributor.authorClemente-Moragón, Agustín
dc.contributor.authorVillena-Gutierrez, Rocio
dc.contributor.authorGómez, Monica
dc.contributor.authorSanz-Rosa, David
dc.contributor.authorDíaz-Guerra, Anabel
dc.contributor.authorPrados, Belén
dc.contributor.authorMedina, Juan Pablo
dc.contributor.authorMontó, Fermí
dc.contributor.authorIvorra, Maria Dolores
dc.contributor.authorMárquez-López, Cristina
dc.contributor.authorCannavo, Alessandro
dc.contributor.authorBernal, Juan A
dc.contributor.authorKoch, Walter J
dc.contributor.authorFuster, Valentin
dc.contributor.authorde la Pompa, Jose Luis
dc.contributor.authorOliver, Eduardo
dc.contributor.authorIbáñez, Borja
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderUnión Europea. Comisión Europeaes_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC)es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderFundación BBVAes_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERCV (Enfermedades Cardiovasculares)es_ES
dc.contributor.funderComunidad de Madrid (España)es_ES
dc.contributor.funderEuropean Science Foundationes_ES
dc.contributor.funderFundación ProCNICes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)es_ES
dc.date.accessioned2022-12-15T12:32:25Z
dc.date.available2022-12-15T12:32:25Z
dc.date.issued2022-11-29
dc.description.abstractAortic stenosis (AS) is associated with left ventricular (LV) hypertrophy and heart failure (HF). There is a lack of therapies able to prevent/revert AS-induced HF. Beta3 adrenergic receptor (β3AR) signaling is beneficial in several forms of HF. Here, we studied the potential beneficial effect of β3AR overexpression on AS-induced HF. Selective β3AR stimulation had a positive inotropic effect. Transgenic mice constitutively overexpressing human β3AR in the heart (c-hβ3tg) were protected from the development of HF in response to induced AS, and against cardiomyocyte mitochondrial dysfunction (fragmented mitochondria with remodeled cristae and metabolic reprogramming featuring altered substrate use). Similar beneficial effects were observed in wild-type mice inoculated with adeno-associated virus (AAV9) inducing cardiac-specific overexpression of human β3AR before AS induction. Moreover, AAV9-hβ3AR injection into wild-type mice at late disease stages, when cardiac hypertrophy and metabolic reprogramming are already advanced, reversed the HF phenotype and restored balanced mitochondrial dynamics, demonstrating the potential of gene-therapy-mediated β3AR overexpression in AS. Mice with cardiac specific ablation of Yme1l (cYKO), characterized by fragmented mitochondria, showed an increased mortality upon AS challenge. AAV9-hβ3AR injection in these mice before AS induction reverted the fragmented mitochondria phenotype and rescued them from death. In conclusion, our results step out that β3AR overexpression might have translational potential as a therapeutic strategy in AS-induced HF.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipSpanish Ministry of Science and Innovation (MICINN) RETOS2019-107332RB-I00, European Commission (ERC-CoG grant N° 819775), ERA-CVD Joint Translational Call 2016 (funded through the Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (ERDF), # AC16/00021), and BBVA foundation grant (# BIO CAR 0265) to B.I. PID2019-104776RB-I00, CB16/11/00399 (CIBER CV), and RD16/0011/0021 (TERCEL) from MCIN/AEI/ https://doi.org/10.13039/501100011033and a grant from the Fundación BBVA (Ref.: BIO14_298) to J.L.d.l.P. E.O. is recipient of funds from Programa de Atracción de Talento (2017-T1/BMD-5185) of Comunidad de Madrid and from a Ramón y Cajal grant (RYC2020- 028884-I) funded by MCIN/AEI/ https://doi.org/10.13039/50110 0011033 and by “ESF Investing in your future. A.P. is benefciary of a FPI fellowship by the MCI (BES-2012–061091), R.V-G. of a Spanish National doctorate fellowship funded by ISCIII (Contratos PFIS FI17/00045) and A.C-M. is benefciary of a FPU fellowship from the MCI (FPU2017/01932). This study was partially supported by the Comunidad de Madrid (RENIM-CM, S2017/BMD-3867 & P2022/ BMD-7403) and cofunded with European structural and investment funds. The CNIC is supported by the ISCIII, the MICINN and the Pro CNIC Foundation, and is a Center of Excellence Severo Ochoa (grant CEX2020-001041-S funded by MICIN/AEI/https://doi.org/10.13039/ 501100011033).es_ES
dc.format.number1es_ES
dc.format.page62es_ES
dc.format.volume117es_ES
dc.identifier.citationBasic Res Cardiol. 2022 Nov 29;117(1):62es_ES
dc.identifier.doi10.1007/s00395-022-00966-zes_ES
dc.identifier.e-issn1435-1803es_ES
dc.identifier.journalBasic research in cardiologyes_ES
dc.identifier.pubmedID36445563es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15275
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RETOS2019-107332RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/ERC-CoG/819775es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-104776RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CB16/11/00399es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0011/0021es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BBVA/BIO14_298es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2017-T1/BMD-5185es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2020- 028884-Ies_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/BES-2012–061091es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PFIS FI17/00045es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU2017/01932es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2017/BMD-3867es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/P2022/ BMD-7403es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/AC16/00021es_ES
dc.relation.publisherversion10.1007/s00395-022-00966-zes_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHeart Failurees_ES
dc.subject.meshAortic Valve Stenosises_ES
dc.subject.meshHumanses_ES
dc.subject.meshMicees_ES
dc.subject.meshAnimalses_ES
dc.subject.meshReceptors, Adrenergic, beta-3es_ES
dc.subject.meshMitochondrial Dynamicses_ES
dc.subject.meshHypertrophy, Left Ventriculares_ES
dc.subject.meshMyocytes, Cardiaces_ES
dc.subject.meshMice, Transgenices_ES
dc.subject.meshMetalloendopeptidaseses_ES
dc.titleBeta-3 adrenergic receptor overexpression reverses aortic stenosis-induced heart failure and restores balanced mitochondrial dynamics.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicatione7d9424a-4126-4043-9250-505d9bc9fdf4
relation.isAuthorOfPublication90ef391b-0278-4cd4-990b-0ef0ca00d082
relation.isAuthorOfPublication558474d4-85be-4127-bda8-59128f707249
relation.isAuthorOfPublicationad8d6052-73cf-4556-a111-22ef8b0a1b50
relation.isAuthorOfPublication6ac0323c-934c-4156-8099-cbf453615d48
relation.isAuthorOfPublication2cac8bb6-2bff-4bf6-8209-bdbd21781786
relation.isAuthorOfPublication.latestForDiscoverye7d9424a-4126-4043-9250-505d9bc9fdf4

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Basic Research in Cardiology 2022 Beta_3 adrenergic receptor overexpression.pdf
Size:
4.87 MB
Format:
Adobe Portable Document Format
Description:
Artículo